Surmodics, Inc. (SRDX): Price and Financial Metrics

Surmodics, Inc. (SRDX)

Today's Latest Price: $36.35 USD

0.09 (0.25%)

Updated Feb 26 4:00pm

Add SRDX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

SRDX Stock Summary

  • The price/operating cash flow metric for Surmodics Inc is higher than 95.12% of stocks in our set with a positive cash flow.
  • For SRDX, its debt to operating expenses ratio is greater than that reported by just 0.37% of US equities we're observing.
  • In terms of twelve month growth in earnings before interest and taxes, Surmodics Inc is reporting a growth rate of -202.36%; that's higher than merely 7.16% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Surmodics Inc are MEET, SYNA, SIMO, TNAV, and ACIA.
  • SRDX's SEC filings can be seen here. And to visit Surmodics Inc's official web site, go to
SRDX Daily Price Range
SRDX 52-Week Price Range

SRDX Stock Price Chart More Charts

SRDX Price/Volume Stats

Current price $36.35 52-week high $58.84
Prev. close $36.26 52-week low $35.71
Day low $36.08 Volume 54,755
Day high $36.66 Avg. volume 72,667
50-day MA $40.32 Dividend yield N/A
200-day MA $41.96 Market Cap 493.92M

Surmodics, Inc. (SRDX) Company Bio

SurModics Inc. provides surface modification and in vitro diagnostic technologies to the healthcare industry. The company operates through two segments, Medical Device and In Vitro Diagnostics. The company was founded in 1979 and is based in Eden Prairie, Minnesota.

SRDX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$36.35$1.87 -95%

We started the process of determining a valid price forecast for Surmodics Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Surmodics Inc ranked in the 8st percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 95%. As for the metrics that stood out in our discounted cash flow analysis of Surmodics Inc, consider:

  • Its compound free cash flow growth rate, as measured over the past 5.76 years, is -0.13% -- higher than only 13.77% of stocks in our DCF forecasting set.
  • As a business, SRDX is generating more cash flow than merely 19.32% of positive cash flow stocks in the Healthcare.
  • The business' balance sheet suggests that 0% of the company's capital is sourced from debt; this is greater than only 0% of the free cash flow producing stocks we're observing.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

CRY, ELAN, GRFS, PHG, and MEDS can be thought of as valuation peers to SRDX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

SRDX Latest News Stream

Event/Time News Detail
Loading, please wait...

SRDX Latest Social Stream

Loading social stream, please wait...

View Full SRDX Social Stream

SRDX Price Returns

1-mo -8.00%
3-mo -11.10%
6-mo -22.76%
1-year -36.37%
3-year 45.11%
5-year 51.14%
YTD -12.26%
2019 -12.34%
2018 68.79%
2017 10.24%
2016 25.31%
2015 -8.28%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7016 seconds.